# Medicare Covers CBD Without FDA Approval and Faces a Lawsuit > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medicare-cbd-policy-regulatory-access/ > **Published:** 2026-04-01T20:02:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:30-04:00 > **Clinical Summary:** Explore Medicare CBD policy regulatory access and the legal challenges surrounding coverage without FDA approval impacting patient access and safety. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic MedicareCbdPolicyRegulatoryAccess Why This Matters Medicare coverage decisions significantly influence [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to cannabis medicines and establish precedent for insurance reimbursement. This coverage without FDA approval creates a regulatory gap that affects clinical decision-making and patient safety protocols. Clinical Summary Medicare is reportedly covering [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) without FDA approval, prompting legal challenges. This represents an unusual departure from Medicare’s typical requirement for FDA-approved medications. The coverage appears to be occurring through specific pathways or interpretations that bypass standard pharmaceutical approval processes. The legal challenge likely centers on Medicare’s authority to cover unapproved substances and potential conflicts with federal [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/). Dr. Caplan’s Take “This creates a concerning precedent where coverage decisions outpace safety and efficacy standards. Clinicians need clear guidance on which [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) meet Medicare’s coverage criteria and what quality standards apply.” Clinical Perspective 🧠 Providers should verify specific coverage criteria with Medicare before recommending CBD products to patients. Document medical necessity clearly and ensure patients understand that coverage doesn’t guarantee product quality or consistency. Monitor for policy changes as this legal challenge progresses. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Medicare%20covers%20CBD%20without%20FDA%20approval%20and%20faces%20a%20lawsuit%20-%20TheStreet%20%40drcaplan&url=https%3A//www.thestreet.com/health/medicare-covers-cbd-without-fda-approval-and-faces-a-lawsuit)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.thestreet.com/health/medicare-covers-cbd-without-fda-approval-and-faces-a-lawsuit)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Medicare%20covers%20CBD%20without%20FDA%20approval%20and%20faces%20a%20lawsuit%20-%20TheStreet%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.thestreet.com/health/medicare-covers-cbd-without-fda-approval-and-faces-a-lawsuit)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.thestreet.com/health/medicare-covers-cbd-without-fda-approval-and-faces-a-lawsuit](https://www.thestreet.com/health/medicare-covers-cbd-without-fda-approval-and-faces-a-lawsuit) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [Does this article relate to Medicare coverage of cannabis products?](#Does_this_article_relate_to_Medicare_coverage_of_cannabis_products) - [What type of cannabis product is primarily discussed?](#What_type_of_cannabis_product_is_primarily_discussed) - [Is this a regulatory or policy update?](#Is_this_a_regulatory_or_policy_update) - [Why should clinicians pay attention to this news?](#Why_should_clinicians_pay_attention_to_this_news) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70 with “Notable Clinical Interest” status. This indicates emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### Does this article relate to Medicare coverage of cannabis products? Yes, based on the Medicare tag, this article appears to discuss Medicare policy regarding cannabis or CBD products. This represents a significant development in healthcare coverage and access to [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). #### What type of cannabis product is primarily discussed? The article focuses on CBD (cannabidiol) as indicated by the CBD tag. CBD is a non-psychoactive compound derived from cannabis that has various therapeutic applications. #### Is this a regulatory or policy update? Yes, this is both a policy and regulatory development as shown by the corresponding tags. It involves changes to healthcare coverage policies and regulatory frameworks surrounding cannabis products. #### Why should clinicians pay attention to this news? This represents emerging policy developments that could affect [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to CBD treatments through Medicare coverage. Healthcare providers should monitor these changes as they may impact treatment options and coverage decisions for their patients. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Medicare covers CBD without FDA approval and faces a lawsuit – TheStreet”, “url”: “https://www.thestreet.com/health/medicare-covers-cbd-without-fda-approval-and-faces-a-lawsuit”, “datePublished”: “2026-04-01T19:04:36Z”, “about”: “medicare covers cbd without fda approval”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [CMS unveils new Medicare pilot for hemp, CBD products – Fierce Healthcare](https://cedclinic.com/medicare-pilot-hemp-cbd-coverage-expands-access/) Learn about the latest Medicare pilot program for hemp and CBD products and its implications for patient access and coverage. [Read More](https://cedclinic.com/medicare-pilot-hemp-cbd-coverage-expands-access/) [Biopharma Company Joins Lawsuit Over CMS Hemp Pilot – EMJ](https://cedclinic.com/cms-hemp-pilot-program-lawsuit/) Explore the ongoing legal challenges involving CMS hemp pilot programs and their impact on the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/). [Explore Details](https://cedclinic.com/cms-hemp-pilot-program-lawsuit/) [Feds Finalize New Rule Allowing Some Hemp Products As Medicare Advantage Benefits](https://cedclinic.com/medicare-hemp-coverage-rule-expands-benefits/) Discover the finalized federal rule permitting certain hemp products as Medicare Advantage benefits and what it means for coverage. [Learn More](https://cedclinic.com/medicare-hemp-coverage-rule-expands-benefits/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).